Show simple item record

AuthorFuruya-Kanamori, Luis
AuthorDoi, Suhail Ar
AuthorOnitilo, Adedayo
AuthorAkhtar, Saghir
Available date2019-12-15T06:29:01Z
Publication Date2019-11-01
Publication NameExpert Opinion on Drug Safetyen_US
Identifierhttp://dx.doi.org/10.1080/14740338.2020.1691167
CitationLuis Furuya-Kanamori, Suhail Ar Doi, Adedayo Onitilo & Saghir Akhtar (2019) Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?, Expert Opinion on Drug Safety, DOI: 10.1080/14740338.2020.1691167
ISSN1474-0338
URIhttp://hdl.handle.net/10576/12398
AbstractRecent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize that the original studies may have produced exaggerated results because of the small baseline risks involved.: A meta-analysis that included 71 trials, 8 different VEGFR-TKIs, and 11 adverse events was re-analyzed. The outcome of interest was re-defined as the complementary outcome (i.e. remaining free of an adverse event). The inverse variance heterogeneity model was used to pool the effect size.: VEGFR-TKIs decreased the risk of remaining free of hypertension by 7% (RR 0.93; 95%CI:0.88-0.97). Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93-0.99), thrombocytopenia (RR 0.91; 95%CI:0.89-0.93), and bleeding (RR 0.96; 95%CI:0.93-0.99) respectively. VEGFR-TKIs were not associated with thrombotic event, myocardial infarction, stroke, venous thrombotic event, pulmonary embolism, left ventricular dysfunction, or QTc interval prolongation.: VEGFR-TKIs are associated with a small increase in risk of patients developing hypertension, arterial thrombotic events, thrombocytopenia, and bleeding. Previous studies overestimated the actual risk associated with VEGFR-TKIs by analyzing the outcome with the lower baseline risk.
Languageen
PublisherTaylor & Francis
Subjectadverse events
Subjectcardiovascular events
Subjectmeta-analysis
Subjectrisk
Subjecttyrosine kinase inhibitors
TitleIs there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
TypeArticle
ESSN1744-764X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record